open access publication

Article, 2024

B cell characteristics define HCV reinfection outcome

Journal of Hepatology, ISSN 1600-0641, 0168-8278, 10.1016/j.jhep.2024.04.004

Contributors

Underwood, Alexander P 0000-0001-7971-6906 [1] [2] [3] Gupta, Money [3] Wu, Bing-Ru 0000-0002-0557-9440 [3] Eltahla, Auda A 0000-0002-2995-8832 [3] Boo, Irene 0000-0003-0923-0972 [4] Wang, Jing Jing [5] Agapiou, David J 0000-0003-3913-3751 [3] Abayasingam, Arunasingam 0000-0002-9406-3058 [3] Reynaldi, Arnold 0000-0002-5529-5542 [3] Keoshkerian, Elizabeth [3] Zhao, Yanran [3] Brasher, Nicholas A 0000-0002-7951-8763 [3] Walker, Melanie Rose 0000-0002-9731-9880 [3] Bukh, Jens Drachmand 0000-0002-7815-4806 [1] [2] Maher, Lisa S 0000-0001-6020-6519 [3] Gordon, Tom [5] Davenport, Miles Philip 0000-0002-4751-1831 [3] Luciani, Fabio 0000-0003-0666-6324 [3] Drummer, Heidi Edelgard 0000-0002-0042-6277 [4] [6] [7] Lloyd, Andrew R 0000-0001-6277-8887 [3] Bull, Rowena Anne 0000-0002-9844-3744 (Corresponding author) [3]

Affiliations

  1. [1] Copenhagen University Hospital
  2. [NORA names: Capital Region of Denmark; Hospital; Denmark; Europe, EU; Nordic; OECD];
  3. [2] University of Copenhagen
  4. [NORA names: KU University of Copenhagen; University; Denmark; Europe, EU; Nordic; OECD];
  5. [3] UNSW Sydney
  6. [NORA names: Australia; Oceania; OECD];
  7. [4] Burnet Institute
  8. [NORA names: Australia; Oceania; OECD];
  9. [5] Flinders University
  10. [NORA names: Australia; Oceania; OECD];

Abstract

BACKGROUND & AIMS: In individuals highly exposed to HCV, reinfection is common, suggesting that natural development of sterilising immunity is difficult. In those that are reinfected, some will develop a persistent infection, while a small proportion repeatedly clear the virus, suggesting natural protection is possible. The aim of this study was to characterise immune responses associated with rapid natural clearance of HCV reinfection. METHODS: Broad neutralising antibodies (nAbs) and Envelope 2 (E2)-specific memory B cell (MBC) responses were examined longitudinally in 15 individuals with varied reinfection outcomes. RESULTS: Broad nAb responses were associated with MBC recall, but not with clearance of reinfection. Strong evidence of antigen imprinting was found, and the B-cell receptor repertoire showed a high level of clonality with ongoing somatic hypermutation of many clones over subsequent reinfection events. Single-cell transcriptomic analyses showed that cleared reinfections featured an activated transcriptomic profile in HCV-specific B cells that rapidly expanded upon reinfection. CONCLUSIONS: MBC quality, but not necessarily breadth of nAb responses, is important for protection against antigenically diverse variants, which is encouraging for HCV vaccine development. IMPACT AND IMPLICATIONS: HCV continues to have a major health burden globally. Limitations in the health infrastructure for diagnosis and treatment, as well as high rates of reinfection, indicate that a vaccine that can protect against chronic HCV infection will greatly complement current efforts to eliminate HCV-related disease. With alternative approaches to testing vaccines, such as controlled human inoculation trials under consideration, we desperately need to identify the correlates of immune protection. In this study, in a small but rare cohort of high-risk injecting drug users who were reinfected multiple times, breadth of neutralisation was not associated with ultimate clearance of the reinfection event. Alternatively, characteristics of the HCV-specific B-cell response associated with B-cell proliferation were. This study indicates that humoral responses are important for protection and suggests that for genetically very diverse viruses, such as HCV, it may be beneficial to look beyond just antibodies as correlates of protection.

Keywords

B cell proliferation, B cell receptor repertoires, B cell responses, B cells, B-cell characteristics, HCV, HCV infection, HCV reinfection, HCV vaccine development, HCV-related disease, NAbs, Strong evidence, aim, alternative approach, analysis, antibodies, antigen, antigenic imprinting, approach, burden, characteristics, chronic HCV infection, clearance, clonality, clones, cohort of high-risk, complement current efforts, correlates of immune protection, correlation, current efforts, development, diagnosis, disease, diverse variants, diverse viruses, drug, drug users, efforts, envelope, events, genetics, health, health burden, health infrastructure, high risk, humoral response, hypermutation, immune protection, immunity, implications, imprinting, individuals, infection, infrastructure, inoculation trials, levels, levels of clonality, limitations, memory B cells, multiple times, nAb responses, natural clearance, natural development, natural protection, neutralisation, neutralising antibodies, outcomes, persistent infection, profile, proliferation, proportion, protection, quality, rare cohort, rate, rate of reinfection, recall, receptor repertoire, reinfection, reinfection events, reinfection outcomes, repertoire, response, single-cell transcriptome analysis, somatic hypermutation, study, test vaccines, time, transcriptome analysis, transcriptome profiling, treatment, trials, users, vaccine, vaccine development, variants, virus

Funders

  • National Health and Medical Research Council
  • Novo Nordisk Foundation

Data Provider: Digital Science